| scholarly article | Q13442814 |
| P356 | DOI | 10.1309/15B6-6DQM-FYYM-78CJ |
| P698 | PubMed publication ID | 16613351 |
| P50 | author | Claes Göran Tropé | Q17112916 |
| P2093 | author name string | Aasmund Berner | |
| Ben Davidson | |||
| Björn Risberg | |||
| Ilvars Silins | |||
| Arild Holth | |||
| Hiep Phuc Dong | |||
| Mari Bunkholt Elstrand | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 451-458 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | American Journal of Clinical Pathology | Q15750224 |
| P1476 | title | NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | |
| P478 | volume | 125 |
| Q36176058 | A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models |
| Q26748905 | Adoptive immunotherapy against ovarian cancer |
| Q55074255 | Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue. |
| Q36745357 | Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. |
| Q57688794 | Antigen-specific active immunotherapy for ovarian cancer |
| Q93081293 | B Cells as an Immune-Regulatory Signature in Ovarian Cancer |
| Q90506533 | B cell and B cell-related pathways for novel cancer treatments |
| Q39381508 | B cell regulation in cancer and anti-tumor immunity. |
| Q38167668 | B cell regulation of anti-tumor immune response |
| Q35444346 | B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. |
| Q93149071 | Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging |
| Q37881763 | Chemokines: key players in cancer progression and metastasis |
| Q90318500 | Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion |
| Q35081677 | HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. |
| Q94546356 | Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study |
| Q42204309 | High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator |
| Q58793402 | High mammographic density in women is associated with protumor inflammation |
| Q26742047 | Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? |
| Q34989820 | Immune cells in the normal ovary and spontaneous ovarian tumors in the laying hen (Gallus domesticus) model of human ovarian cancer |
| Q35138135 | Immunity and immune suppression in human ovarian cancer |
| Q26996829 | Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer |
| Q36021465 | Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. |
| Q40982736 | Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses |
| Q30244418 | Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q93052035 | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| Q49724715 | Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. |
| Q33754724 | Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients |
| Q92921946 | Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer |
| Q53538525 | Parathyroid chief cell adenoma associated with massive chronic parathyroiditis in a woman with hyperparathyroidism. |
| Q58582595 | Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients |
| Q80580929 | Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) |
| Q33813250 | Prognostic impact of lymphocytes in soft tissue sarcomas |
| Q37334966 | Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck |
| Q33488520 | Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors |
| Q28082828 | Targeted immune therapy of ovarian cancer |
| Q35110486 | Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity |
| Q39172481 | The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities |
| Q90452290 | The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy |
| Q37613407 | The immune system in the pathogenesis of ovarian cancer |
| Q37118142 | The impact of T-cell immunity on ovarian cancer outcomes |
| Q36186338 | The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer |
| Q26751022 | Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms |
| Q27021878 | Tumor infiltrating lymphocytes in ovarian cancer |
| Q36413361 | Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals |
| Q41894399 | Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway |
| Q64921196 | With Great Age Comes Great Metastatic Ability: Ovarian Cancer and the Appeal of the Aging Peritoneal Microenvironment. |
| Q87944215 | [B cells in head and neck oncology] |
| Q37223836 | p53 autoantibodies, cytokine levels and ovarian carcinogenesis |
Search more.